<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS108045</article-id>
<article-id pub-id-type="doi">10.1101/2020.12.08.416636</article-id>
<article-id pub-id-type="archive">PPR251080</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Persistent Cellular Immunity to SARS-CoV-2 Infection</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Breton</surname>
<given-names>Gaëlle</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="fn" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mendoza</surname>
<given-names>Pilar</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="fn" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hagglof</surname>
<given-names>Thomas</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="fn" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Oliveira</surname>
<given-names>Thiago Y.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schaefer-Babajew</surname>
<given-names>Dennis</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gaebler</surname>
<given-names>Christian</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Turroja</surname>
<given-names>Martina</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hurley</surname>
<given-names>Arlene</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Caskey</surname>
<given-names>Marina</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Nussenzweig</surname>
<given-names>Michel C.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA</aff>
<aff id="A2">
<label>2</label>Hospital Program Direction, The Rockefeller University, New York, NY 10065, USA</aff>
<aff id="A3">
<label>3</label>Howard Hughes Medical Institute</aff>
<author-notes>
<corresp id="CR1">
<label>#</label>Send correspondence to Gaëlle Breton <email>gbreton@rockefeller.edu</email>, Michel Nussenzweig <email>nussen@rockefeller.edu</email>
</corresp>
<fn id="FN1">
<label>*</label>
<p id="P1">Equal contribution</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>11</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>09</day>
<month>12</month>
<year>2020</year>
</pub-date>
<permissions>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P2">SARS-CoV-2 is responsible for an ongoing pandemic that affected millions of individuals around the globe. To gain further understanding of the immune response in recovered individuals we measured T cell responses in paired samples obtained an average of 1.3 and 6.1 months after infection from 41 individuals. The data indicate that recovered individuals show persistent polyfunctional SARS-CoV-2 antigen specific memory that could contribute to rapid recall responses. In addition, recovered individuals show enduring immune alterations in relative numbers of CD4<sup>+</sup> and CD8<sup>+</sup> T cells, expression of activation/exhaustion markers, and cell division.</p>
<sec id="S1">
<title>Summary</title>
<p id="P3">We show that SARS-CoV-2 infection elicits broadly reactive and highly functional memory T cell responses that persist 6 months after infection. In addition, recovered individuals show enduring immune alterations in CD4<sup>+</sup> and CD8<sup>+</sup> T cells compartments.</p>
</sec>
</abstract>
</article-meta>
</front>
<body>
<sec id="S2" sec-type="intro">
<title>Introduction</title>
<p id="P4">Individuals infected with SARS-CoV-2 develop both cellular and humoral immune responses to the virus (<xref ref-type="bibr" rid="R28">Robbiani et al., 2020</xref>, <xref ref-type="bibr" rid="R10">Gaebler et al., 2020</xref>, <xref ref-type="bibr" rid="R37">Suthar et al., 2020</xref>, <xref ref-type="bibr" rid="R9">Ni et al., 2020</xref>, <xref ref-type="bibr" rid="R13">Grifoni et al., 2020</xref>, <xref ref-type="bibr" rid="R25">Peng et al., 2020</xref>, <xref ref-type="bibr" rid="R34">Sekine et al., 2020</xref>, <xref ref-type="bibr" rid="R13">Rydyznski Moderbacher et al., 2020</xref>, <xref ref-type="bibr" rid="R2">Braun et al., 2020</xref>, Zhou et al., 2020). Antibody responses include most of the structural proteins expressed by the virus and neutralizing antibodies directed primarily to the receptor binding domain of the spike trimer (S) (<xref ref-type="bibr" rid="R28">Robbiani et al., 2020</xref>, <xref ref-type="bibr" rid="R10">Gaebler et al., 2020</xref>, <xref ref-type="bibr" rid="R37">Suthar et al., 2020</xref>, <xref ref-type="bibr" rid="R9">Ni et al., 2020</xref>, <xref ref-type="bibr" rid="R20">Lumley et al., 2020</xref>). Cellular immune responses can be broad but vary widely (<xref ref-type="bibr" rid="R13">Grifoni et al., 2020</xref>, <xref ref-type="bibr" rid="R25">Peng et al., 2020</xref>, <xref ref-type="bibr" rid="R34">Sekine et al., 2020</xref>, <xref ref-type="bibr" rid="R13">Rydyznski Moderbacher et al., 2020</xref>, <xref ref-type="bibr" rid="R2">Braun et al., 2020</xref>, Zhou et al., 2020), and lymphopenia is a prominent feature of more severe infection, affecting CD4<sup>+</sup> and CD8<sup>+</sup> T cells, as well as B cells (<xref ref-type="bibr" rid="R40">Tavakolpour et al., 2020</xref>, <xref rid="R5" ref-type="bibr">Chen and John Wherry, 2020</xref>, Huang et al., 2020, <xref ref-type="bibr" rid="R12">Giamarellos-Bourboulis et al., 2020</xref>, Tan et al., 2020, <xref ref-type="bibr" rid="R17">Kuri-Cervantes et al., 2020</xref>, <xref ref-type="bibr" rid="R17">Mathew et al., 2020</xref>).</p>
<p id="P5">Careful studies of immune phenotypes in moderate, severe and recovered individuals revealed T cell responses, ranging from undetectable to robust CD8<sup>+</sup> T cell and/or CD4<sup>+</sup> T cell activation and proliferation (<xref ref-type="bibr" rid="R13">Grifoni et al., 2020</xref>, <xref ref-type="bibr" rid="R25">Peng et al., 2020</xref>, <xref ref-type="bibr" rid="R2">Braun et al., 2020</xref>, <xref ref-type="bibr" rid="R22">Neidleman et al., 2020</xref>). During acute infection, T cells displayed a highly activated cytotoxic phenotype, whereas convalescent patients harbored polyfunctional SARS-CoV-2-specific T cells that display a stem like memory phenotype (<xref ref-type="bibr" rid="R34">Sekine et al., 2020</xref>, <xref ref-type="bibr" rid="R22">Neidleman et al., 2020</xref>, <xref ref-type="bibr" rid="R13">Weiskopf et al., 2020</xref>). In addition, there is cross-reactivity with seasonal/common cold coronaviruses that suggests that these responses may be associated with a milder clinical course (<xref ref-type="bibr" rid="R34">Sekine et al., 2020</xref>, Le Bert et al., 2020).</p>
<p id="P6">Coronaviruses elicit variable levels of persistent Immunity to other coronaviruses. For example, individuals infected with MERS remain immune for only 1–3 years, while protection from seasonal coronaviruses is short-lived (Wu et al., 2007, <xref ref-type="bibr" rid="R9">Edridge et al., 2020</xref>, Tang et al., 2011). Although there is increasing evidence that cellular immunity plays a major role in resolution of COVID-19, little is known about the persistence of cellular immunity to SARS-CoV-2 (<xref ref-type="bibr" rid="R29">Rodda et al., 2020</xref>). This is a particularly important issue when considering an individual’s ability to resist a second exposure to the virus. To determine whether cellular immunity to SARS-CoV-2 persists half a year after infection we examined paired samples obtained an average of 1.3 and 6.1 months after infection from a cohort of 41 COVID-19-convalescent volunteers (<xref ref-type="bibr" rid="R28">Robbiani et al., 2020</xref>, <xref ref-type="bibr" rid="R10">Gaebler et al., 2020</xref>). All of the individuals tested had RT-PCR confirmed SARS-CoV-2 infection or were close contacts that had seroconverted and were RT-PCR negative at the second time point (<xref ref-type="bibr" rid="R10">Gaebler et al., 2020</xref>). The 41 individuals were 63.4% male and 36.6% female, representing a range of different ages, 24-73 years old, and disease severity but skewed to mild forms of the disease (Table 1).</p>
</sec>
<sec id="S3" sec-type="results">
<title>Results</title>
<sec id="S4">
<title>Changes in Circulating T cells After COVID-19</title>
<p id="P7">The phenotypic landscape of circulating T cells was determined by high-dimensional flow cytometry at both time points and compared to pre-COVID-19 samples from healthy individuals (n=20). Global high-dimensional mapping with t-distributed stochastic neighbor embedding (tSNE) revealed significant persistent alterations in SARS-CoV-2 recovered individuals (<xref ref-type="fig" rid="F1">Fig. 1A</xref>). Relatively under-represented T cell clusters in recovered individuals included Clusters 1, 2, 3, 4, and 14 (<xref ref-type="fig" rid="F1">Fig. 1B-D</xref> and <xref ref-type="supplementary-material" rid="SD1">Suppl. Fig. 1B</xref>). Clusters 1,3 and 4 showed a phenotype consistent with CD4<sup>+</sup> central memory T cells (Tcm, CD45RA<sup>-</sup>CD27<sup>+</sup>CCR7<sup>+</sup>, <xref ref-type="fig" rid="F1">Fig. 1B-C</xref> and <xref ref-type="supplementary-material" rid="SD1">Fig. S1A</xref>). In contrast, cluster 14 displayed features of CD8<sup>+</sup> Tcm (CD45RA<sup>-</sup>CD27<sup>+</sup>CCR7<sup>+</sup>, <xref ref-type="fig" rid="F1">Fig. 1B-C</xref> and <xref ref-type="supplementary-material" rid="SD1">Fig. S1A</xref>). Examples of clusters showing a relative increase over control included clusters 10 and 13 (<xref ref-type="fig" rid="F1">Fig. 1D</xref> and <xref ref-type="supplementary-material" rid="SD1">Suppl. Fig. 1B</xref>). Cluster 10 resembles CD8<sup>+</sup> T effector cells (Te, CD45RA<sup>+</sup>CD27<sup>-</sup>CCR7<sup>-,</sup> <xref ref-type="fig" rid="F1">Fig. 1B-D</xref> and <xref ref-type="supplementary-material" rid="SD1">Fig. S1A</xref>) and cluster 13 CD8<sup>+</sup> T effector memory cells (Tem, CD45RA<sup>+</sup>CD27<sup>-</sup>CCR7<sup>-,</sup> <xref ref-type="fig" rid="F1">Fig. 1B-D</xref> and <xref ref-type="supplementary-material" rid="SD1">Fig. S1A</xref>). The relative distribution of all of the clusters described above remained abnormal at the 6.1 month time point (<xref ref-type="fig" rid="F1">Fig. 1D</xref> and <xref ref-type="supplementary-material" rid="SD1">Suppl. Fig. 1B</xref>). We conclude that there are significant shifts in circulating CD4<sup>+</sup> and CD8<sup>+</sup> T cell compartments that persist for half a year after SARS-CoV-2 infection.</p>
<p id="P8">To further examine changes in the T cell compartment we queried the data by traditional gating (<xref ref-type="supplementary-material" rid="SD1">Suppl. Fig. 2</xref>). The relative proportions of circulating CD4<sup>+</sup> T cells decreased significantly 1.3 months after infection whereas the circulating CD8<sup>+</sup> T cells increased; but both returned to near physiologic levels by 6.1 months (<xref ref-type="fig" rid="F2">Fig. 2A</xref> and <xref ref-type="fig" rid="F2">2B</xref>). PD-1 expression is modulated on activated and exhausted T cells and is associated with acute and prolonged changes in T cell function after viral infection in mice (<xref ref-type="bibr" rid="R32">Schonrich and Raftery, 2019</xref>, <xref ref-type="bibr" rid="R16">Jubel et al., 2020</xref>). PD-1 expression was decreased on CD4<sup>+</sup> and CD8<sup>+</sup> T cells at both time points (<xref ref-type="fig" rid="F2">Fig. 2C</xref> and <xref ref-type="fig" rid="F2">2D</xref>). Consistent with these alterations, TIGIT, Tim-3 and CD25 expression were also abnormal (<xref ref-type="fig" rid="F2">Fig. 2C</xref> and <xref ref-type="fig" rid="F2">2D</xref>). We conclude that there are persistent changes in the distribution of circulating CD4<sup>+</sup> and CD8<sup>+</sup> T cells and their expression of activation/exhaustion markers.</p>
<p id="P9">Consistent with the clustering analysis, central memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells decreased, and this defect persisted throughout the observation period (<xref ref-type="fig" rid="F2">Fig. 2E</xref> and <xref ref-type="fig" rid="F2">2F</xref>). In addition, there was an increase in cycling CD4<sup>+</sup> and CD8<sup>+</sup> T cells (Ki67<sup>+</sup>) at both time points (<xref ref-type="fig" rid="F2">Fig. 2G</xref> and <xref ref-type="fig" rid="F2">2H</xref>). Both central memory and cycling cells also showed lower levels of PD-1 expression at both time points (<xref ref-type="supplementary-material" rid="SD1">Suppl. Fig. 3A-D</xref>). In contrast, we found no significant changes in circulating TFH or Treg cells (<xref ref-type="supplementary-material" rid="SD1">Suppl. Fig. 4</xref>). Thus, the more traditional gating strategy is generally consistent with the tSNE analysis.</p>
</sec>
<sec id="S5">
<title>SARS-CoV-2-antigen specific CD4<sup>+</sup> T cells</title>
<p id="P10">To investigate SARS-CoV-2-antigen specific CD4<sup>+</sup> T cells, we stimulated the cells with a collection of pooled SARS-CoV-2 peptides <italic>in vitro</italic>. COVID-19 convalescent individuals were compared to healthy donors by tSNE using high dimensional flow cytometry. Antigen-specific CD4<sup>+</sup> T cells expressing memory markers as well as IL-2, IFN-γ, TNF-α and CD154 were markedly increased in COVID-19 recovered individuals compared to healthy donors, but the relative frequency of these cells decreased at the 6.1 month time point (clusters 2, 3, 4 and 6, <xref ref-type="fig" rid="F3">Fig. 3A-D</xref> and <xref ref-type="supplementary-material" rid="SD1">Suppl. Fig. 5A</xref>). The magnitude of the decrease in these responses between the time points varied between 22-32% depending on the cluster (<xref ref-type="fig" rid="F3">Fig. 3D</xref>) and on the individual peptide pool (<xref ref-type="supplementary-material" rid="SD1">Suppl. Fig. 5B</xref>). In contrast, responses to CMV peptides remained unchanged between the 2 time points (<xref ref-type="supplementary-material" rid="SD1">Suppl. Fig. 6</xref>). We conclude that SARS-CoV-2 antigen specific CD4<sup>+</sup> T cells are induced during acute infection and are only slightly reduced after 6.1 months.</p>
<p id="P11">To characterize SARS-CoV-2 antigen specific cytokine producing CD4<sup>+</sup> T cells we analyzed the high dimensional flow cytometry data by traditional gating (<xref ref-type="fig" rid="F4">Fig. 4</xref> and <xref ref-type="supplementary-material" rid="SD1">Suppl. Fig. 2</xref>). IL-2, INFγ, and TNFα responses to peptide pools corresponding to Spike (S1 and S2), NCAP, Memb, AP3a, and CMV control were measured independently at both time points (<xref ref-type="fig" rid="F4">Fig. 4A-C</xref>). In all cases, responses to the individual peptide pools were elevated above control at both time points, and all but NCAP and Memb responses remained stable between the time points (<xref ref-type="fig" rid="F4">Fig. 4A-C</xref>). Among the individuals tested 97.5% and 95% responded to at least one of the antigens at 1.3 and 6.1 months respectively (<xref ref-type="supplementary-material" rid="SD1">Suppl. Fig. 7A-C</xref>). When all cytokines are considered together, we find a significant increase in antigen specific CD4<sup>+</sup> T cell responses to all of the individual peptide pools at both time points compared to control (<xref ref-type="fig" rid="F4">Fig. 4A</xref>). The increase in CD4<sup>+</sup> T cell cytokine responses to the individual peptide pools and the overall combination of all SARS-CoV-2 antigens was not driven by any single cytokine but instead reflected increases in each of the three cytokines measured (<xref ref-type="supplementary-material" rid="SD1">Suppl. Fig. 7D</xref>). Moreover, when all antigen specific responses are considered in aggregate, the fraction of responding CD4<sup>+</sup> T cells remains significantly elevated and is not different between the 2 time points (<xref ref-type="fig" rid="F4">Fig. 4A</xref>, All). Antigen specific memory CD4<sup>+</sup> memory T cells (CD45RA<sup>+</sup>CD27<sup>+</sup>) were similarly elevated at the two time points (<xref ref-type="fig" rid="F4">Fig. 4B</xref>). Finally, there was no significant change in the CD4<sup>+</sup> T cell response by the same individuals to the control CMV peptide pool (<xref ref-type="fig" rid="F4">Fig. 4A-C</xref>).</p>
<p id="P12">Polyfunctional cytokine responses are associated with effective cellular immune responses (<xref ref-type="bibr" rid="R33">Seder et al., 2008</xref>, <xref ref-type="bibr" rid="R19">Lin et al., 2015</xref>, <xref ref-type="bibr" rid="R1">Betts et al., 2006</xref>). Polyfunctional CD4<sup>+</sup> T cells responses to each of the individual peptide pools were significantly elevated at the early time point and remained so after 6.1 months (<xref ref-type="fig" rid="F4">Fig. 4C</xref>). The magnitude of these responses was directly correlated with antibodies to the SARS-CoV-2 receptor binding domain (<xref ref-type="supplementary-material" rid="SD1">Suppl. Fig. 8</xref>). However, there was a decrease in polyfunctional CD4<sup>+</sup> T cell responses to NCAP and Memb antigens at 6.1 months which is also reflected in a 22% decrease in the overall tri-functional response to the combined SARS-CoV-2 peptide libraries (<xref ref-type="fig" rid="F4">Fig. 4C</xref>, All). In contrast, CD4<sup>+</sup> T cells that produced only a single cytokine were only elevated in response to Memb and only at the early time point (<xref ref-type="fig" rid="F4">Fig. 4C</xref>). We conclude that robust polyfunctional CD4<sup>+</sup> T cell responses persist for 6.1 months after SARS-CoV-2 infection but decrease significantly when compared to an earlier time point.</p>
</sec>
<sec id="S6">
<title>SARS-CoV-2 antigen specific CD8<sup>+</sup> T cells</title>
<p id="P13">To examine antigen specific CD8<sup>+</sup> T cell responses we measured production of Mip-1β, CD107a, IL-2, INF-γ and TNF-α in response to stimulation with SARS-CoV-2 peptide pools <italic>in vitro</italic>. In contrast to CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cell responses were far more variable and generally less robust making tSNE analysis less reliable and therefore these responses were only analyzed by traditional gating (<xref ref-type="fig" rid="F5">Fig. 5</xref> and <xref ref-type="supplementary-material" rid="SD1">Suppl. Fig. 9</xref>). Although 95% of the donors tested responded to at least 1 of the peptide pools at both 1.3 and 6.1 months, the percentage of responding cells was low (<xref ref-type="fig" rid="F5">Fig. 5A</xref>). When all peptide responses were pooled, we found significant Mip-1β, and INF-γ responses at both time points, while CD107a was only increased above control at 1.3 months. Polyfunctional responses that included at least 3 different cytokines were also elevated at both time points (<xref ref-type="fig" rid="F5">Fig. 5B</xref>). We conclude that although we detect fewer antigen specific CD8<sup>+</sup> than CD4<sup>+</sup> T cells to SARS-CoV-2, they persist 6.1 months after infection.</p>
</sec>
</sec>
<sec id="S7" sec-type="discussion">
<title>Discussion</title>
<p id="P14">Most effective vaccines and anamnestic responses to pathogens are mediated by neutralizing antibodies (<xref ref-type="bibr" rid="R26">Plotkin, 2020</xref>, <xref ref-type="bibr" rid="R15">Inoue et al., 2018</xref>, <xref ref-type="bibr" rid="R43">Weisel and Shlomchik, 2017</xref>). Consistent with this notion, neutralizing antibodies are protective against SARS-CoV-2 infection in animal models (<xref ref-type="bibr" rid="R8">Deng et al., 2020</xref>) and appear to correlate with protection in vaccinated humans (<xref ref-type="bibr" rid="R10">Gaebler and Nussenzweig, 2020</xref>). However, antibody responses are dependent on specialized helper T cells that control the activation and selection of antibody producing plasma and memory B cells (<xref ref-type="bibr" rid="R42">Victora and Nussenzweig, 2012</xref>, <xref ref-type="bibr" rid="R7">Crotty, 2015</xref>).</p>
<p id="P15">CD4<sup>+</sup> and CD8<sup>+</sup> T cells can also contribute directly to protection against SARS-CoV (Le Bert et al., 2020, Tang et al., 2011, Yang et al., 2006, <xref ref-type="bibr" rid="R4">Channappanavar et al., 2014</xref>) and other viral pathogens in animal models (<xref ref-type="bibr" rid="R31">Schmitz et al., 1999</xref>, Shoukry et al., 2003, Snyder, 2011). In addition, control of human viral pathogens such as HIV-1 is associated with CD8<sup>+</sup> T cells in rare elite controllers (<xref ref-type="bibr" rid="R6">Collins et al., 2020</xref>). To gain further understanding into whether SARS-CoV-2 infection is associated with enduring responses we examined cellular immunity to SARS-CoV-2 in paired samples collected 1.3 and 6.1 months after infection. Similar to SARS-CoV and MERS infections, SARS-CoV-2 antigen specific memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells persist and would be expected to play role in protection against re-exposure.</p>
<p id="P16">In addition to persistent antigen specific memory responses, chronic viral infections such as HIV are associated with lasting immune perturbations (<xref ref-type="bibr" rid="R3">Breton et al., 2013</xref>), but little is known about acute viral infections. SARS-CoV-2 is an acute infection that typically resolves after 2-3 weeks and in rare instances leads to severe lung disease and mortality (<xref ref-type="bibr" rid="R27">Richardson et al., 2020</xref>, <xref ref-type="bibr" rid="R2">O’Driscoll et al., 2020</xref>). The cohort we examined is biased toward milder forms of the disease, nevertheless, CD4<sup>+</sup> and CD8<sup>+</sup> T cell subset distribution, cell division and expression of activation/exhaustion markers remain altered 6 months after SARS-CoV-2 infection. These abnormalities were not directly associated with persistent symptoms and their impact on the overall immune health of the individual remains to be determined.</p>
</sec>
<sec id="S8" sec-type="materials | methods">
<title>Materials and Methods</title>
<sec id="S9">
<title>Study participants</title>
<p id="P17">Study participants (n = 61) were residents of the Greater New York City tri-state region, 20 of whom were SARS-CoV-2 unexposed (pre-pandemic, median age: 52.5 years old, 45% female), and 41 were SARS-CoV-2-infected (median age: 45 years old; 36.6% female). Previously enrolled study participants (<xref ref-type="bibr" rid="R28">Robbiani et al., 2020</xref>) were asked to return for a 6-month follow-up visit at the Rockefeller University Hospital in New York from August 31 through October 16, 2020. All of the individuals tested had RT-PCR confirmed SARS-CoV-2 infection or were close contacts that seroconverted. A summary of the participants’ clinical characteristics is presented in Table 1 and has been extensively described elsewhere (<xref ref-type="bibr" rid="R28">Robbiani et al., 2020</xref>, <xref ref-type="bibr" rid="R10">Gaebler et al., 2020</xref>).</p>
</sec>
<sec id="S10">
<title>Cell preparation</title>
<p id="P18">Blood samples were collected an average of 1.3 and 6.1 months post infection (Table 1). Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood by density gradient centrifugation (Ficoll-Paque™) and cryopreserved in 90% heat-activated fetal bovine serum (FBS) plus 10% DMSO in liquid nitrogen. Thawed PBMCs were washed and resuspended at 2×10<sup>6</sup> cells/ml with RPMI 1640 supplemented with 10% heat inactivated human serum (GemCell) and 10 U/ml Benzonase. For cell stimulation experiments cells were rested at 37°C and 5% CO<sub>2</sub> for 8 hours prior to stimulation with peptides for use in intracellular cytokine staining assays.</p>
</sec>
<sec id="S11">
<title>Synthetic COVID-19 peptides</title>
<p id="P19">Pool of 315 peptides (15mers with 11 aa overlap) (Spike glycoprotein, delivered in two subpools of 158 (S1 pool) &amp; 157 (S2 pool) peptides), 102 peptides (Nucleoprotein), 53 peptides (Membrane protein) and 66 peptides (Protein 3a, AP3a) of SARS-CoV-2 were purchased from JPT (Berlin, Germany). Pool of 138 peptides (15mers with 11 aa overlap) derived from 65 kDa phosphoprotein (pp65) of Human cytomegalovirus (CMV) (JPT) was used as control. Staphylococcus Enterotoxin B (SEB) (Sigma-Aldrich, St-Louis, MO, USA) was used at a final concentration of 1μg/ml as a positive stimulation control. Peptides were reconstituted in high grade DMSO (Sigma-Aldrich, St-Louis, MO, USA) at a concentration of 0.1 mg/ml and used at a final concentration of 0.25 μg/ml in a maximum of 0.2% DMSO. PBMCs with peptide diluent (0.2% DMSO) served as the negative control.</p>
</sec>
<sec id="S12">
<title>Cell Stimulation and intracellular staining</title>
<p id="P20">Cells were stimulated for 12h with SARS-CoV-2 peptide pools (0.25 μg/ml) in the presence of αCD28/αCD49d co-stimulatory antibodies (BD FastImmune™, BD Biosciences, San Diego, CA, USA), 5 μg/ml brefeldin A (Sigma-Aldrich, St-Louis, MO, USA) and 5 μg/ml Monensin. (BD GolgiStop™ BD Biosciences, San Diego, CA, USA), and anti-CD107a-PE-Cy5 (Clone H4A3) (the staining for CD107a is carried out during cell activation in this assay). A negative control containing PBMCs and co-stimulatory antibodies from the same subject, with DMSO, was also included for each assay. Following stimulation, cells were washed with PBS and were first stained with CCR7 (Clone 3D12) at 37°C for 20 min in PBS containing 2% FBS. Cells were then surface stained for 30 min in the dark at 4°C with viability reagent (BD Horizon™ Fixable Viability Stain, BD Biosciences, San Diego, CA, USA) and a 29-color cocktail of monoclonal antibodies (mAbs) containing surface antibodies against CD19 (Clone SJ25C1), CD20 (Clone 2H7), CD66b (Clone G10F5), CD14 (Clone M5E2), CD16 (Clone 3G8), CD56 (Clone B159), CD4 (Clone OKT4), CD8 (Clone RPA-T8), CD45RA (Clone HI100), CD27 (Clone M-T271), CD57 (Clone NK-1), CD25 (Clone 2A3), CXCR5 (Clone RF8B2), CD127 (Clone HIL-7R-M21), PD-1 (Clone EH12.1), TIGIT (Clone 741182), Tim-3 (Clone 7D3) and CD69 (Clone FN50). The cells were then washed with PBS containing 2% FBS and permeabilized according to the manufacturer’s instructions using a Foxp3/Transcription Factor Staining Buffer Set (eBioscience™) and stained with intracellular antibodies against CD3 (Clone SK7), MIP-1b (Clone D21-1351), IL-2 (Clone MQ1-17H12), IFN-g (Clone B27), TNF-a (Clone MAb11), FoxP3 (Clone 236A/E7), Ki67 (Clone ki-67), CD154 (Clone 24-3) and CD137 (Clone 4B4-1). After labelling, cells were washed and fixed in PBS containing 2% paraformaldehyde and stored at 4°C prior to flow cytometry acquisition within 24 hours.</p>
</sec>
<sec id="S13">
<title>Phenotypic characterization and surface staining</title>
<p id="P21">Cells from all donors were initially stained with CCR7 (Clone 3D12) at 37°C for 20 min in PBS containing 2% FBS. Cells were then stained with a 29-color staining cocktail containing viability reagent and surface antibodies against CD19 (Clone SJ25C1), CD20 (Clone 2H7), CD66b (Clone G10F5), CD14 (Clone M5E2), CD16 (Clone 3G8), CD56 (Clone B159), CD3 (Clone SK7), CD4 (Clone OKT4), CD8 (Clone RPA-T8), CD45RA (Clone HI100), CD27 (Clone M-T271), CD95 (Clone DX2), NKG2A (Clone 131411), NKG2C (Clone 134591), PD-1 (Clone EH12.1), TIGIT (Clone 741182), TIM-3 (Clone 7D3), CD152 (Clone BNI3), CD272 (Clone J168-540), CD134 (Clone ACT35), CD274 (Clone MIH1), CD273 (Clone MIH18), CD96 (Clone 6F9), CD357 (Clone V27-580), CD160 (Clone BY55), CD137 (Clone 4B4-1), CD223 (Clone T47-530), CD278 (Clone C398.4A), CD28 (Clone CD28.2) and CD244 (Clone eBioC1.7). Titrated antibodies were added to 2 million cells in 50 μl of PBS containing 2% FBS for 30 minutes at 4°C. Washed cells were then fixed in 2% formaldehyde and stored at 4°C until analysis.</p>
</sec>
<sec id="S14">
<title>Flow cytometry analysis</title>
<p id="P22">All events -approximately 1,200,000 to 1,800,000 events per sample-were collected on a BD FACSymphony™A5 Cell Analyzer (BD Biosciences, San Diego, CA, USA). The lymphocytes were gated for further analysis, as described in Figure S2, using Flowjo™ Software Version 9.9.6 (BD, USA). For cytokine expression, we subtracted the background in the negative control. To ensure equivalent fluorescence intensities (median fluorescence intensity or MFI) from one experiment to another, we used Rainbow beads (Spherotech, Inc, Lake Forest, IL, USA). For every run, rainbow beads were acquired first and the voltages were adjusted if necessary to accommodate both daily variations and larger changes in performance such as would be seen after cytometer maintenance and alignment.</p>
</sec>
<sec id="S15">
<title>High-dimensional data analysis of flow cytometry data</title>
<p id="P23">viSNE and FlowSOM analyses were performed on Cytobank (<ext-link ext-link-type="uri" xlink:href="https://cytobank.org">https://cytobank.org</ext-link>). viSNE analysis was performed using equal sampling of 5000 cells (for total T cell phenotyping analysis, <xref ref-type="fig" rid="F1">Fig. 1</xref>), or proportional sampling (for antigen-specific CD4<sup>+</sup> T cell analysis, <xref ref-type="fig" rid="F3">Fig. 3</xref>) from each FCS file, with 7500 iterations, a perplexity of 30, and a theta of 0.5. The following markers were used to generate viSNE maps: CD273, CD96, NKG2C, CD152, TIGIT, CD272, CD134, CD45RA, CD137, CD366, CD95, CD279, CD16, CD274, CD27, CD56, CD357, CCR7, CD223, CD278, CD28, CD244, NKG2a, CD4, and CD8 (for total T cells, <xref ref-type="fig" rid="F1">Fig. 1</xref>), and CXCR5, CD127, MIP1b, CD137, IL-2, TIGIT, CD45RA, CD57, CD25, TIM-3, CD69, PD-1, CD16, IFNg, CD27, CD56, TNFa, Ki67, ICOS, CD107a, FoxP3, CD154 (for antigen-specific CD4<sup>+</sup> T cells, <xref ref-type="fig" rid="F3">Fig. 3</xref> and <xref ref-type="supplementary-material" rid="SD1">Suppl. Figs. 5</xref>-<xref ref-type="supplementary-material" rid="SD1">6</xref>). Resulting viSNE maps were fed into the FlowSOM clustering algorithm (Van <xref ref-type="bibr" rid="R41">Gassen et al., 2015</xref>). The self-organizing map (SOM) was generated using hierarchical consensus clustering on the tSNE axes.</p>
</sec>
<sec id="S16">
<title>Statistical analysis</title>
<p id="P24">Statistical analyses were performed using Prism 7.0 (GraphPad). Significances between matched groups were calculated using paired t-test whereas differences between unmatched groups were compared using unpaired t-test, or one-way ANOVA. Correlations were performed using the Spearman rank correlation test.</p>
</sec>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary Figures</label>
<media xlink:href="EMS108045-supplement-Supplementary_Figures.pdf" mimetype="application" mime-subtype="pdf" id="N66715" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD2">
<label>Supplementary Materials</label>
<media xlink:href="EMS108045-supplement-Supplementary_Materials.pdf" mimetype="application" mime-subtype="pdf" id="N66724" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S17">
<title>Acknowledgments</title>
<p>We thank all study participants who devoted time to our research; Drs. Barry Coller and Sarah Schlesinger, the Rockefeller University Hospital Clinical Research Support Office and nursing staff. All members of the M.C.N. laboratory for helpful discussions and Maša Jankovic for laboratory support.</p>
<sec id="S18">
<title>Funding</title>
<p>This work was supported by NIH grant P01-AI138398-S1 (M.C.N.) and 2U19AI111825 (M.C.N.). T.H. is supported by an international postdoctoral fellowship from the Swedish Research Council. M.C.N. is a Howard Hughes Medical Institute Investigator.</p>
</sec>
</ack>
<fn-group>
<fn fn-type="con" id="FN2">
<p id="P25">
<bold>Author contributions</bold>
</p>
<p id="P26">G.B. and M.C.N. conceived and designed the study. G.B., P.M. and T.H. carried out and analyzed the experiments. D.S.B., M.C. and C.G. designed clinical protocols. M.C., M.T. and A.H. recruited participants and executed clinical protocols. T.Y.O. advised on bioinformatic analysis. G.B., P.M, T.H. and M.C.N. wrote the manuscript with input from all co-authors.</p>
</fn>
<fn id="FN3" fn-type="conflict">
<p id="P27">
<bold>Competing interests</bold>
</p>
<p id="P28">None.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Betts</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Nason</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>West</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>De Rosa</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Migueles</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lederman</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Benito</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Goepfert</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Connors</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roederer</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells</article-title>
<source>Blood</source>
<year>2006</year>
<volume>107</volume>
<fpage>4781</fpage>
<lpage>9</lpage>
</element-citation>
</ref>
<ref id="R2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braun</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Loyal</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Frentsch</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wendisch</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Georg</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kurth</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hippenstiel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dingeldey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kruse</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Fauchere</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Baysal</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19</article-title>
<source>Nature</source>
<year>2020</year>
<volume>587</volume>
<fpage>270</fpage>
<lpage>274</lpage>
</element-citation>
</ref>
<ref id="R3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Breton</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Chomont</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Takata</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fromentin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ahlers</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Filali-Mouhim</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Riou</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Boulassel</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Routy</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Yassine-Diab</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sekaly</surname>
<given-names>RP</given-names>
</name>
</person-group>
<article-title>Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection</article-title>
<source>J Immunol</source>
<year>2013</year>
<volume>191</volume>
<fpage>2194</fpage>
<lpage>204</lpage>
</element-citation>
</ref>
<ref id="R4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Channappanavar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fett</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Meyerholz</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection</article-title>
<source>J Virol</source>
<year>2014</year>
<volume>88</volume>
<fpage>11034</fpage>
<lpage>44</lpage>
</element-citation>
</ref>
<ref id="R5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>John Wherry</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>T cell responses in patients with COVID-19</article-title>
<source>Nat Rev Immunol</source>
<year>2020</year>
<volume>20</volume>
<fpage>529</fpage>
<lpage>536</lpage>
</element-citation>
</ref>
<ref id="R6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collins</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Gaiha</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>BD</given-names>
</name>
</person-group>
<article-title>CD8(+) T cells in HIV control, cure and prevention</article-title>
<source>Nat Rev Immunol</source>
<year>2020</year>
<volume>20</volume>
<fpage>471</fpage>
<lpage>482</lpage>
</element-citation>
</ref>
<ref id="R7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crotty</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>A brief history of T cell help to B cells</article-title>
<source>Nat Rev Immunol</source>
<year>2015</year>
<volume>15</volume>
<fpage>185</fpage>
<lpage>9</lpage>
</element-citation>
</ref>
<ref id="R8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>818</fpage>
<lpage>823</lpage>
</element-citation>
</ref>
<ref id="R9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edridge</surname>
<given-names>AWD</given-names>
</name>
<name>
<surname>Kaczorowska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hoste</surname>
<given-names>ACR</given-names>
</name>
<name>
<surname>Bakker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Loens</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jebbink</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Matser</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kinsella</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Rueda</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ieven</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Seasonal coronavirus protective immunity is short-lasting</article-title>
<source>Nat Med</source>
<year>2020</year>
<volume>26</volume>
<fpage>1691</fpage>
<lpage>1693</lpage>
</element-citation>
</ref>
<ref id="R10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaebler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nussenzweig</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>All eyes on a hurdle race for a SARS-CoV-2 vaccine</article-title>
<source>Nature</source>
<year>2020</year>
<volume>586</volume>
<fpage>501</fpage>
<lpage>502</lpage>
</element-citation>
</ref>
<ref id="R11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaebler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Lorenzi</surname>
<given-names>JCC</given-names>
</name>
<name>
<surname>Muecksch</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Finkin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tokuyama</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ladinsky</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jankovic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schaefer-Babajew</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>TY</given-names>
</name>
<etal/>
</person-group>
<article-title>Evolution of Antibody Immunity to SARS-CoV-2</article-title>
<source>bioRxiv</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giamarellos-Bourboulis</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Netea</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Rovina</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Akinosoglou</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Antoniadou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Antonakos</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Damoraki</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gkavogianni</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Adami</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Katsaounou</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ntaganou</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure</article-title>
<source>Cell Host Microbe</source>
<year>2020</year>
<volume>27</volume>
<fpage>992</fpage>
<lpage>1000 e3</lpage>
</element-citation>
</ref>
<ref id="R13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grifoni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Weiskopf</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ramirez</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Mateus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dan</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Moderbacher</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Rawlings</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Sutherland</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Premkumar</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jadi</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Marrama</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals</article-title>
<source>Cell</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group>
<article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>
<source>Lancet</source>
<year>2020</year>
<volume>395</volume>
<fpage>497</fpage>
<lpage>506</lpage>
</element-citation>
</ref>
<ref id="R15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inoue</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Moran</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Shinnakasu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Phan</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Kurosaki</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Generation of memory B cells and their reactivation</article-title>
<source>Immunol Rev</source>
<year>2018</year>
<volume>283</volume>
<fpage>138</fpage>
<lpage>149</lpage>
</element-citation>
</ref>
<ref id="R16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jubel</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Barbati</surname>
<given-names>ZR</given-names>
</name>
<name>
<surname>Burger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wirtz</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Schildberg</surname>
<given-names>FA</given-names>
</name>
</person-group>
<article-title>The Role of PD-1 in Acute and Chronic Infection</article-title>
<source>Front Immunol</source>
<year>2020</year>
<volume>11</volume>
<fpage>487</fpage>
</element-citation>
</ref>
<ref id="R17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuri-Cervantes</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pampena</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Ittner</surname>
<given-names>CAG</given-names>
</name>
<name>
<surname>Weisman</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Agyekum</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Mathew</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Baxter</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Vella</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Kuthuru</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group>
<article-title>Comprehensive mapping of immune perturbations associated with severe COVID-19</article-title>
<source>Sci Immunol</source>
<year>2020</year>
<volume>5</volume>
</element-citation>
</ref>
<ref id="R18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le Bert</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Kunasegaran</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tham</surname>
<given-names>CYL</given-names>
</name>
<name>
<surname>Hafezi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chng</surname>
<given-names>MHY</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Linster</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chia</surname>
<given-names>WN</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>457</fpage>
<lpage>462</lpage>
</element-citation>
</ref>
<ref id="R19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Finak</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ushey</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Seshadri</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hawn</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Frahm</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Scriba</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Mahomed</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hanekom</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Bart</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Pantaleo</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>
<article-title>COMPASS identifies T-cell subsets correlated with clinical outcomes</article-title>
<source>Nat Biotechnol</source>
<year>2015</year>
<volume>33</volume>
<fpage>610</fpage>
<lpage>6</lpage>
</element-citation>
</ref>
<ref id="R20">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lumley</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>O’DONNELL</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Stoesser</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Howarth</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hatch</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Marsden</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>S</given-names>
</name>
<name>
<surname>James</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Peck</surname>
<given-names>LJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Antibodies to SARS-CoV-2 are associated with protection against reinfection</article-title>
<source>medRxiv</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mathew</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Giles</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Baxter</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Oldridge</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Greenplate</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Alanio</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kuri-Cervantes</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pampena</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>D’ANDREA</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Manne</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
</element-citation>
</ref>
<ref id="R22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neidleman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Frouard</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gill</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Mcgregor</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>T</given-names>
</name>
<name>
<surname>George</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kosters</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>WC</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2-specific T cells exhibit unique features characterized by robust helper function, lack of terminal differentiation, and high proliferative potential</article-title>
<source>bioRxiv</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ni</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>YQ</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals</article-title>
<source>Immunity</source>
<year>2020</year>
<volume>52</volume>
<fpage>971</fpage>
<lpage>977 e3</lpage>
</element-citation>
</ref>
<ref id="R24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’DRISCOLL</surname>
<given-names>M</given-names>
</name>
<name>
<surname>DOS Santos</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>DAT</given-names>
</name>
<name>
<surname>Azman</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Paireau</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fontanet</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cauchemez</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Salje</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Age-specific mortality and immunity patterns of SARS-CoV-2</article-title>
<source>Nature</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Mentzer</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dejnirattisai</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Rostron</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Supasa</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lopez-Camacho</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19</article-title>
<source>Nat Immunol</source>
<year>2020</year>
<volume>21</volume>
<fpage>1336</fpage>
<lpage>1345</lpage>
</element-citation>
</ref>
<ref id="R26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plotkin</surname>
<given-names>SA</given-names>
</name>
</person-group>
<article-title>Updates on immunologic correlates of vaccine-induced protection</article-title>
<source>Vaccine</source>
<year>2020</year>
<volume>38</volume>
<fpage>2250</fpage>
<lpage>2257</lpage>
</element-citation>
</ref>
<ref id="R27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richardson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hirsch</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Narasimhan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Mcginn</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>THE Northwell</surname>
<given-names>C-RC</given-names>
</name>
<name>
<surname>Barnaby</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Chelico</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>SL</given-names>
</name>
<etal/>
</person-group>
<article-title>Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area</article-title>
<source>JAMA</source>
<year>2020</year>
<volume>323</volume>
<fpage>2052</fpage>
<lpage>2059</lpage>
</element-citation>
</ref>
<ref id="R28">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robbiani</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Gaebler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Muecksch</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lorenzi</surname>
<given-names>JCC</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Agudelo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Gazumyan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Finkin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hagglof</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Convergent antibody responses to SARS-CoV-2 in convalescent individuals</article-title>
<source>Nature</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R29">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodda</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Netland</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shehata</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pruner</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Morawski</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Thouvenel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Takehara</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Eggenberger</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hemann</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Waterman</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Fahning</surname>
<given-names>ML</given-names>
</name>
<etal/>
</person-group>
<article-title>Functional SARS-CoV-2-specific immune memory persists after mild COVID-19</article-title>
<source>medRxiv</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rydyznski Moderbacher</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ramirez</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Dan</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Grifoni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hastie</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Weiskopf</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Belanger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Abbott</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity</article-title>
<source>Cell</source>
<year>2020</year>
<volume>183</volume>
<fpage>996</fpage>
<lpage>1012 e19</lpage>
</element-citation>
</ref>
<ref id="R31">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmitz</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Kuroda</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Santra</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sasseville</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Lifton</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Racz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tenner-Racz</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Dalesandro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Scallon</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Ghrayeb</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes</article-title>
<source>Science</source>
<year>1999</year>
<volume>283</volume>
<fpage>857</fpage>
<lpage>60</lpage>
</element-citation>
</ref>
<ref id="R32">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schonrich</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Raftery</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance</article-title>
<source>Front Cell Infect Microbiol</source>
<year>2019</year>
<volume>9</volume>
<fpage>207</fpage>
</element-citation>
</ref>
<ref id="R33">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seder</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Darrah</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Roederer</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>T-cell quality in memory and protection: implications for vaccine design</article-title>
<source>Nat Rev Immunol</source>
<year>2008</year>
<volume>8</volume>
<fpage>247</fpage>
<lpage>58</lpage>
</element-citation>
</ref>
<ref id="R34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sekine</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Perez-Potti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rivera-Ballesteros</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Stralin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gorin</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Olsson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Llewellyn-Lacey</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kamal</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bogdanovic</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Muschiol</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wullimann</surname>
<given-names>DJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19</article-title>
<source>Cell</source>
<year>2020</year>
<volume>183</volume>
<fpage>158</fpage>
<lpage>168 e14</lpage>
</element-citation>
</ref>
<ref id="R35">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shoukry</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>Grakoui</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Houghton</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chien</surname>
<given-names>DY</given-names>
</name>
<name>
<surname>Ghrayeb</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Reimann</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection</article-title>
<source>J Exp Med</source>
<year>2003</year>
<volume>197</volume>
<fpage>1645</fpage>
<lpage>55</lpage>
</element-citation>
</ref>
<ref id="R36">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snyder</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Buffered memory: a hypothesis for the maintenance of functional, virus-specific CD8(+) T cells during cytomegalovirus infection</article-title>
<source>Immunol Res</source>
<year>2011</year>
<volume>51</volume>
<fpage>195</fpage>
<lpage>204</lpage>
</element-citation>
</ref>
<ref id="R37">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suthar</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Kauffman</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Mantus</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Linderman</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Hudson</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Vanderheiden</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nyhoff</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Adekunle</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Affer</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients</article-title>
<source>Cell Rep Med</source>
<year>2020</year>
<volume>1</volume>
<comment>100040</comment>
</element-citation>
</ref>
<ref id="R38">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>YQ</given-names>
</name>
<name>
<surname>WANG</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study</article-title>
<source>Signal Transduct Target Ther</source>
<year>2020</year>
<volume>5</volume>
<fpage>33</fpage>
</element-citation>
</ref>
<ref id="R39">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Quan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xin</surname>
<given-names>ZT</given-names>
</name>
<name>
<surname>Wrammert</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>TB</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Richardus</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>WC</given-names>
</name>
</person-group>
<article-title>Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study</article-title>
<source>J Immunol</source>
<year>2011</year>
<volume>186</volume>
<fpage>7264</fpage>
<lpage>8</lpage>
</element-citation>
</ref>
<ref id="R40">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tavakolpour</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rakhshandehroo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>EX</given-names>
</name>
<name>
<surname>Rashidian</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Lymphopenia during the COVID-19 infection: What it shows and what can be learned</article-title>
<source>Immunol Lett</source>
<year>2020</year>
<volume>225</volume>
<fpage>31</fpage>
<lpage>32</lpage>
</element-citation>
</ref>
<ref id="R41">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Gassen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Callebaut</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Van Helden</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Lambrecht</surname>
<given-names>BN</given-names>
</name>
<name>
<surname>Demeester</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dhaene</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Saeys</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data</article-title>
<source>Cytometry A</source>
<year>2015</year>
<volume>87</volume>
<fpage>636</fpage>
<lpage>45</lpage>
</element-citation>
</ref>
<ref id="R42">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Victora</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Nussenzweig</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>Germinal centers</article-title>
<source>Annu Rev Immunol</source>
<year>2012</year>
<volume>30</volume>
<fpage>429</fpage>
<lpage>57</lpage>
</element-citation>
</ref>
<ref id="R43">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weisel</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Shlomchik</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Memory B Cells of Mice and Humans</article-title>
<source>Annu Rev Immunol</source>
<year>2017</year>
<volume>35</volume>
<fpage>255</fpage>
<lpage>284</lpage>
</element-citation>
</ref>
<ref id="R44">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiskopf</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schmitz</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Raadsen</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Grifoni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Okba</surname>
<given-names>NMA</given-names>
</name>
<name>
<surname>Endeman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Van Den Akker</surname>
<given-names>JPC</given-names>
</name>
<name>
<surname>Molenkamp</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Koopmans</surname>
<given-names>MPG</given-names>
</name>
<name>
<surname>Van Gorp</surname>
<given-names>ECM</given-names>
</name>
<name>
<surname>Haagmans</surname>
<given-names>BL</given-names>
</name>
<etal/>
</person-group>
<article-title>Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome</article-title>
<source>Sci Immunol</source>
<year>2020</year>
<volume>5</volume>
</element-citation>
</ref>
<ref id="R45">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>XY</given-names>
</name>
<name>
<surname>Na</surname>
<given-names>DY</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lan</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>LF</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>GD</given-names>
</name>
</person-group>
<article-title>Duration of antibody responses after severe acute respiratory syndrome</article-title>
<source>Emerg Infect Dis</source>
<year>2007</year>
<volume>13</volume>
<fpage>1562</fpage>
<lpage>4</lpage>
</element-citation>
</ref>
<ref id="R46">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>LT</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>ZL</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>ZT</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>ZX</given-names>
</name>
<name>
<surname>Koup</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Bailer</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>WU</surname>
<given-names>CY</given-names>
</name>
</person-group>
<article-title>Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients</article-title>
<source>Clin Immunol</source>
<year>2006</year>
<volume>120</volume>
<fpage>171</fpage>
<lpage>8</lpage>
</element-citation>
</ref>
<ref id="R47">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>R</given-names>
</name>
<name>
<surname>To</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>LIU</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Luk</surname>
<given-names>TY</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Yeung</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>
<article-title>Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses</article-title>
<source>Immunity</source>
<year>2020</year>
<volume>53</volume>
<fpage>864</fpage>
<lpage>877 e5</lpage>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Fig. 1</label>
<caption>
<title>Persistent longitudinal changes in the phenotypic landscape of T cells in individuals recovered from COVID-19.</title>
<p>(<bold>A</bold>) Global viSNE projection of pooled T cells for all participants pooled shown in background contour plots, with overlaid projections of concatenated controls, convalescent patients 1.3 months, and convalescent 6.1 months, respectively. (<bold>B</bold>) viSNE projection of pooled T cells for all participants of T cell clusters identified by FlowSOM clustering. (<bold>C</bold>) Column-scaled <italic>z</italic>-scores of median fluorescence intensity (MFI) as indicated by cluster and marker. (<bold>D</bold>) Frequency of T cells from each group in FlowSOM clusters indicated. Each dot represents an individual with COVID-19 at 1.3 months (dark blue for CD4<sup>+</sup> T cells and dark red for CD8<sup>+</sup> T cells) or 6.1 months (light blue for CD4<sup>+</sup> T cells and orange for CD8<sup>+</sup> T cells) as well as control individuals (green).</p>
</caption>
<graphic xlink:href="EMS108045-f001"/>
</fig>
<fig id="F2" position="float">
<label>Fig. 2</label>
<caption>
<title>T cell abnormalities persist after 6.1 months.</title>
<p>(<bold>A</bold>) Frequency of CD4<sup>+</sup> T cells out of total CD3<sup>+</sup> T cells. (<bold>B</bold>) PD-1, TIGIT, TIM-3 and CD25 expression of CD4<sup>+</sup> T cells. (<bold>C</bold>) Frequency of CD8<sup>+</sup> T cells out of total CD3<sup>+</sup> T cells. (<bold>D</bold>) PD-1, TIGIT, TIM-3 and CD25 expression of CD8<sup>+</sup> T cells. (<bold>E</bold>) Percentage of Tscm, Tn, Tcm, Ttm, Tem, and Ttd CD4<sup>+</sup> T cells. (<bold>F</bold>) Percentage of Tscm, Tn, Tcm, Ttm, Tem, and Te CD8<sup>+</sup> T cells. (<bold>G</bold>) Frequency of cycling CD4<sup>+</sup> T cells. (<bold>H</bold>) Frequency of cycling CD8<sup>+</sup> T cells. Each dot represents an individual with COVID-19 at 1.3 months (dark blue for CD4<sup>+</sup> T cells and dark red for CD8<sup>+</sup> T cells) or 6.1 months (light blue for CD4<sup>+</sup> T cells and orange for CD8<sup>+</sup> T cells) as well as control individuals (green). Significance determined by paired t test for comparisons between time points within individuals and unpaired t test for comparison between controls and COVID-19 individuals. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p>
</caption>
<graphic xlink:href="EMS108045-f002"/>
</fig>
<fig id="F3" position="float">
<label>Fig. 3</label>
<caption>
<title>Antigen-specific CD4<sup>+</sup> T cells dynamics in COVID-19 convalescent individuals.</title>
<p>(<bold>A</bold>) viSNE representations of CD137<sup>+</sup> CD154<sup>+</sup> SARS-CoV-2-stimulated CD4<sup>+</sup> T cells in unexposed individuals (controls) and COVID-19 convalescent individuals pooled. Density plots from each group concatenated is overlaid on the total contour viSNE plot. (<bold>B</bold>) viSNE representation of antigen-specific CD4<sup>+</sup> T cell clusters, identified by FlowSOM clustering. (<bold>C</bold>) Column-scaled <italic>z</italic>-scores of median fluorescence intensity (MFI) as indicated by cluster and marker. (<bold>D</bold>) Percentage of antigen-specific CD4<sup>+</sup> cells in the indicated FlowSOM clusters. Each bar represents the mean percentage for all COVID-19 convalescent individuals for the indicated SARS-CoV-2 peptide pools. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p>
</caption>
<graphic xlink:href="EMS108045-f003"/>
</fig>
<fig id="F4" position="float">
<label>Fig. 4</label>
<caption>
<title>SARS-CoV-2-specific CD4<sup>+</sup> T cells responses in convalescent COVID-19 individuals.</title>
<p>Longitudinal analysis of COVID-19 specific CD4<sup>+</sup> T cell responses in paired samples obtained 1.3 months and 6.1 months after infection. Cytokine production (IL-2, IFN-γ, and TNF-α) by CD4<sup>+</sup> T cells analyzed by Intracellular Cytokine Staining (ICS). Spike (Aggregation of responses to Spike peptide pool S1 and S2), Nucleocapsid (NCAP) Membrane (Memb) and non-structural protein 3a (AP3a) peptide pools responses by controls (n=20), and convalescent COVID-19 individuals (n=41). <bold>(A)</bold> Combined frequency of SARS-CoV-2 specific CD4<sup>+</sup> T cells that produce either IL-2, IFN-γ, and/or TNF-α. <bold>(B)</bold> Frequency of SARS-CoV-2 specific memory CD4<sup>+</sup> T cells (CD45RA<sup>-</sup> CD27<sup>+</sup>) that produce either IL-2, IFN-γ, and/or TNF-α. (<bold>C</bold>) Frequency of SARS-CoV-2-specific CD4<sup>+</sup> T cells that produce either 3 cytokines, 2 cytokines or 1 cytokine. Each dot represents an individual at 1.3 months (dark blue) or 6.1 months (light blue) or control individuals (green).Significance determined by paired t test for comparisons between time points within individuals and unpaired t test for comparison between controls and COVID-19 individuals. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p>
</caption>
<graphic xlink:href="EMS108045-f004"/>
</fig>
<fig id="F5" position="float">
<label>Fig. 5</label>
<caption>
<title>SARS-CoV-2-specific CD8<sup>+</sup> T cells responses in convalescent COVID-19 individuals.</title>
<p>Longitudinal analysis of COVID-19 specific CD8<sup>+</sup> T cell responses in paired samples obtained from the same individual at 1.3 months and 6.1 months after infection. Cytokine production (MIP-1β, CD107a, IL-2, IFN-γ, and TNF-α) by CD8<sup>+</sup> T cells analyzed by Intracellular Cytokine Staining (ICS). Spike (Aggregation of responses to spike peptide pool S1 and S2), Nucleocapsid (NCAP) Membrane (Memb) and non-structural protein 3a (AP3a) peptide pools responses by controls (n=20), and convalescent COVID-19 individuals (n=41). <bold>(A)</bold> Frequency of SARS-CoV-2 specific CD8<sup>+</sup> T cells that produce MIP-1β, CD107a, IL-2, IFN-γ, or TNF-α. <bold>(B)</bold> Frequency of SARS-CoV-2 specific CD8<sup>+</sup> T cells that produce either 5 cytokines, 4 cytokines or 3 cytokines. Each dot represents an individual at 1.3 months (dark red) or 6.1 months (orange) or control individuals (green). Significance determined by paired t test for comparisons between time points within individuals and unpaired T test for comparison between controls and COVID-19 individuals. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p>
</caption>
<graphic xlink:href="EMS108045-f005"/>
</fig>
</floats-group>
</article>
